Fondazione del Piemonte per l'Oncologia - IRCCS - Ematologia
Welcome,         Profile    Billing    Logout  
 3 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Scalabrini, Delia Rota
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

Active, not recruiting
3
84
Europe
Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone
Fondazione EMN Italy Onlus
Multiple Myeloma, New Diagnosis Tumor
01/26
01/26
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
122
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
04/27
04/30
Bigliardi, Sara
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting
N/A
104
Europe
Venetoclax plus HMA
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
12/22
12/23
FIL_MIMYC, NCT06588205: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
12/27
12/27
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Recruiting
N/A
552
Europe
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Fondazione Italiana Linfomi - ETS
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
02/26
02/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Frascione, Pio Manlio Mirko
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Scalabrini, Delia Rota
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

Active, not recruiting
3
84
Europe
Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone
Fondazione EMN Italy Onlus
Multiple Myeloma, New Diagnosis Tumor
01/26
01/26
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
122
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
04/27
04/30
Bigliardi, Sara
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting
N/A
104
Europe
Venetoclax plus HMA
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
12/22
12/23
FIL_MIMYC, NCT06588205: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
12/27
12/27
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Recruiting
N/A
552
Europe
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Fondazione Italiana Linfomi - ETS
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
02/26
02/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Frascione, Pio Manlio Mirko
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38

Download Options